Compare TNXP & CNDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | CNDT |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | 51000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 234.2M |
| IPO Year | 2008 | 2016 |
| Metric | TNXP | CNDT |
|---|---|---|
| Price | $13.47 | $1.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 425.9K | ★ 972.0K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $13,107,000.00 | ★ $3,042,000,000.00 |
| Revenue This Year | $558.11 | $2.01 |
| Revenue Next Year | $38.29 | $4.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $9.40 | $1.15 |
| 52 Week High | $34.00 | $2.98 |
| Indicator | TNXP | CNDT |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 55.67 |
| Support Level | $11.98 | $1.32 |
| Resistance Level | $13.36 | $2.05 |
| Average True Range (ATR) | 0.79 | 0.09 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 60.55 | 57.33 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation, as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments, namely Commercial Industries, which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas, of which the majority of revenue is generated in the United States.